• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by PainReform Ltd.

    10/16/24 4:35:07 PM ET
    $PRFX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PRFX alert in real time by email
    6-K 1 zk2432144.htm 6-K


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    Form 6-K
     
    Report of Foreign Private Issuer
     
    Pursuant to Rule 13a-16 or 15d-16
    of the Securities Exchange Act of 1934
     
    For the month of October 2024
     
    Commission File Number: 001-39481
     
    PainReform Ltd.
    (Translation of registrant’s name into English)
     
    65 Yigal Alon St., Tel Aviv 6744316
    Israel
    (Address of principal executive offices)
     
    Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
     
    Form 20-F ☒    Form 40-F ☐


    This Report on Form 6-K (including exhibits attached hereto) is hereby incorporated by reference into the registrant’s Registration Statements on Form S-8 (Registration No. 333-257968 and 333-265902) and Form F-3 (Registration No. 333-254982, 333-276485, 333-277954, and 333-282264), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.
     

    On October 16, 2024, PainReform Ltd. (the “Company”) entered into an At The Market Offering Agreement (the “Offering Agreement”) with H.C. Wainwright & Co., LLC, as sales agent (“Wainwright”), pursuant to which the Company may offer and sell, from time to time through Wainwright ordinary shares of the Company, no par value (the “Ordinary Shares”), having an aggregate offering price of up to $1.35 million (the “Shares”).
     
    The offer and sale of the Shares will be made pursuant to a shelf registration statement on Form F-3 and the related prospectus (File No. 333-282264) filed by the Company with the Securities and Exchange Commission (the “SEC”) on September 20, 2024, and declared effective by the SEC on October 3, 2024, as supplemented by a prospectus supplement dated October 16, 2024, filed with the SEC pursuant to Rule 424(b) under the Securities Act of 1933, as amended (the “Securities Act”).

    Pursuant to the Offering Agreement, sales of Shares may be made in transactions that are deemed to be “at-the-market” offerings as defined in Rule 415 under the Securities Act, including sales made directly on or through The Nasdaq Capital Market, or any other existing trading market in the Unites States for the Company’s Shares, sales made to or through a market maker other than on an exchange or otherwise, directly to Wainwright as principal, in negotiated transactions at market prices prevailing at the time of sale or at prices related to such prevailing market prices and/or in any other method permitted by law. Wainwright will use commercially reasonable efforts consistent with its normal trading and sales practices and applicable law and regulations to sell the Shares pursuant to the Offering Agreement from time to time, based upon instructions from the Company, including any price or size limits or other customary parameters or conditions the Company may impose.
     
    The offering of Shares pursuant to the Offering Agreement will terminate upon the earliest of (a) the termination of the Offering Agreement by Wainwright or the Company, as permitted therein, and (c) the mutual agreement of the parties. The Company will pay Wainwright a fixed commission rate equal to 3.0% of the gross sales price of the Shares sold pursuant to the Offering Agreement and has agreed to provide Wainwright with customary indemnification and contribution rights.
     
    The Company will also reimburse Wainwright for certain specified expenses in connection with entering into the Offering Agreement. The Offering Agreement contains customary representations and warranties and conditions to the sale of the Shares pursuant thereto.
     
    The foregoing description of the Offering Agreement is not complete and is qualified in its entirety by reference to the full text of such agreement, a copy of which is filed herewith as Exhibit 10.1 to this Report on Form 6-K and is incorporated herein by reference. A copy of the opinion of Doron, Tikotzky, Kantor, Gutman, Amit, Gross & Co. relating to the offer and sale of the Shares is attached as Exhibit 5.1 hereto.
     
    This Report on Form 6-K shall not constitute an offer to sell, or the solicitation of an offer to buy, the Shares discussed herein, nor shall there be any offer, solicitation, or sale of securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.


    Exhibit Index
     
    Exhibit No.
     
    Description
    5.1

    Opinion of Doron, Tikotzky, Kantor, Gutman, Amit, Gross & Co.
     
     
    10.1

    At The Market Offering Agreement, dated October 16, 2024, between PainReform Ltd. and H.C. Wainwright & Co., LLC
     
     
    23.1

    Consent of Doron, Tikotzky, Kantor, Gutman, Amit, Gross & Co. (included in Exhibit 5.1)
     

    SIGNATURES
     
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
     
    Date: October 16, 2024
    By:
    /s/ Ehud Geller
     
     
    Ehud Geller
     
     
    Interim Chief Executive Officer
     

    Get the next $PRFX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PRFX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PRFX
    SEC Filings

    View All

    SEC Form 6-K filed by PRF Technologies Ltd.

    6-K - PRF Technologies Ltd. (0001801834) (Filer)

    2/11/26 8:54:35 AM ET
    $PRFX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by PRF Technologies Ltd.

    6-K - PRF Technologies Ltd. (0001801834) (Filer)

    2/3/26 4:16:05 PM ET
    $PRFX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by PainReform Ltd.

    6-K - PAINREFORM LTD. (0001801834) (Filer)

    1/20/26 9:07:43 AM ET
    $PRFX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRFX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    PRF Technologies Wins Another European Utility-Scale Solar Deployment, Expanding DeepSolar's Installed Commercial Base

    TEL AVIV, Israel, Feb. 11, 2026 (GLOBE NEWSWIRE) -- PRF Technologies (NASDAQ:PRFX) ("PRF" or the "Company"), through its DeepSolar™ AI-driven solar analytics business unit, today announced the signing of a software-as-a-service (SaaS) agreement with Shikun & Binui Energy for the deployment of DeepSolar at the 71 megawatt (MW) Satu Mare photovoltaic site in Romania. The Satu Mare project is a utility-scale solar plant owned and operated by Shikun & Binui Energy. Under the agreement, DeepSolar will provide continuous analytics and performance monitoring designed to enhance operational visibility, support proactive asset management, and enable data-driven decision-making throughout the proje

    2/11/26 8:30:00 AM ET
    $PRFX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PRF Technologies Files Its First Patent Application for Solar Plant Micro-Climate Forecast Modeling Designed to Improve Energy Production Forecast Accuracy

    Patent filing follows acceptance into the NVIDIA Connect Program  Proprietary software targets weather forecast-driven revenue optimization, reduced penalty risk, and improved market performance for utility-scale solar assets TEL AVIV, Israel, Jan. 20, 2026 (GLOBE NEWSWIRE) -- PRF Technologies Ltd. (NASDAQ:PRFX) ("PRF" or the "Company") (formerly "PainReform") today announced that it has filed a patent application covering proprietary methods for solar plant–level micro-climate modeling designed to significantly improve the accuracy of solar energy production forecasts in competitive electric utility markets. The patent follows acceptance into the prestigious NVIDIA Connect Program and

    1/20/26 9:05:00 AM ET
    $PRFX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PainReform Ltd. Changes Name to PRF Technologies Ltd. Reflecting Expansion into Diversified Healthcare and AI-Driven Energy Platforms

    TEL AVIV, Israel, Jan. 15, 2026 (GLOBE NEWSWIRE) -- PRF Technologies Ltd. (NASDAQ:PRFX) ("PRF" or the "Company") (formerly "PainReform") today announced its corporate name change to PRF Technologies Ltd. following shareholder approval at the Company's Annual General Meeting held on Tuesday, January 6, 2026. The Company's Nasdaq ticker symbol will remain PRFX. The approved name change is intended to reflect the Company's evolution into a diversified innovation platform spanning specialty pharmaceuticals, advanced drug-delivery technologies, and AI-driven renewable-energy analytics, marking a strategic shift beyond its original single-product focus. Over the past 18 months, PRF has signifi

    1/15/26 4:05:00 PM ET
    $PRFX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRFX
    Leadership Updates

    Live Leadership Updates

    View All

    PainReform Provides Year-End Business Update and Reports Progress Towards Commencing Phase 3 Trial of PRF-110 for Non-Opiate Post-Operative Pain Relief

    HERZLIYA, Israel, March 18, 2021 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today provided a year-end business update.  Significant events and achievements during the fourth quarter 2020 and subsequent period: Preparation for the first Phase 3 clinical trial, for patients undergoing bunionectomy surgery, is expected to begin by mid-2021Announced the engagement of Lotus Clinical Research as the Company’s clinical research organization to conduct the Phase 3 clinical trials under the leadership of Dr. Neil SinglaAnnounced the appointment of Ri

    3/18/21 9:15:00 AM ET
    $PRFX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PainReform Appoints Rita Keynan as Vice President of Pharmaceutical Operations

    HERZLIYA, Israel, Jan. 06, 2021 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced the appointment of Rita Keynan as Vice President of Pharmaceutical Operations. Mrs. Keynan brings over 25 years of managerial experience in the pharmaceutical industry. Mrs. Keynan has been responsible for drug development from early phase trials through NDA filings, including managing all chemistry, manufacturing and control (CMC) activities supporting product development, clinical supplies, scale-up, regulatory submissions and commercial manufacturing

    1/6/21 8:30:00 AM ET
    $PRFX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRFX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by PainReform Ltd.

    SC 13G/A - PAINREFORM LTD. (0001801834) (Subject)

    11/14/24 4:25:42 PM ET
    $PRFX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by PainReform Ltd.

    SC 13G/A - PAINREFORM LTD. (0001801834) (Subject)

    11/13/24 11:18:32 AM ET
    $PRFX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by PainReform Ltd.

    SC 13D/A - PAINREFORM LTD. (0001801834) (Subject)

    8/29/24 4:00:27 PM ET
    $PRFX
    Biotechnology: Pharmaceutical Preparations
    Health Care